Drug Profile
Research programme: cancer immunotherapies - Arcus Biosciences
Alternative Names: LAG-3 antibody-Arcus Biosciences; STING targeting candidates-Arcus Biosciences; TIM-3 antibody-Arcus Biosciences; TLR4 targeting candidates-Arcus BiosciencesLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Arcus Biosciences
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators; MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 19 Sep 2017 Arcus Biosciences and Taiho Pharmaceutical enter into option and license agreement to develop and commercialise immunotherapies for Cancer in Asia, including Japan and excluding China
- 19 Sep 2017 Arcus Biosciences plans a clinical trials of its immunotherapies for Cancer in 2018